{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:03:01Z","timestamp":1790694181210,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Research Center for Pharmaceutical Nanotechnology"},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.phrs.2020.104790","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T21:41:07Z","timestamp":1586382067000},"page":"104790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens"],"prefix":"10.1016","volume":"156","author":[{"given":"Azita","family":"Moradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Pourseif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Parvizpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadollah","family":"Omidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.104790_bib0005","first-page":"370","article-title":"Freedman-Cass D. Colon cancer, version 1.2017, nccn clinical practice guidelines in oncology","volume":"15","author":"Benson","year":"2017","journal-title":"J. Compr. Canc. Netw."},{"issue":"66","key":"10.1016\/j.phrs.2020.104790_bib0010","first-page":"7","article-title":"Cancer statistics, 2016","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2020.104790_bib0015","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1053\/j.gastro.2009.12.065","article-title":"The chromosomal instability pathway in colon cancer","volume":"138","author":"Pino","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.104790_bib0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/scbi.1998.0078","article-title":"Genes and environment in the etiology of colorectal cancer","volume":"8","author":"Gertig","year":"1998","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2020.104790_bib0025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.18632\/oncoscience.59","article-title":"Genetic pathways, prevention, and treatment of sporadic colorectal cancer","volume":"1","author":"Mundade","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.phrs.2020.104790_bib0030","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.phrs.2020.104790_bib0035","doi-asserted-by":"crossref","first-page":"145","DOI":"10.15171\/bi.2019.19","article-title":"Functional expression and impact of testis-specific gene antigen 10 in breast cancer: a combined in vitro and in silico analysis","volume":"9","author":"Asgharzadeh","year":"2019","journal-title":"Bioimpacts"},{"key":"10.1016\/j.phrs.2020.104790_bib0040","doi-asserted-by":"crossref","first-page":"21834","DOI":"10.1038\/srep21834","article-title":"In vivo detection of small tumour lesions by multi-pinhole spect applying a (99m)tc-labelled nanobody targeting the epidermal growth factor receptor","volume":"6","author":"Kruwel","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104790_bib0045","doi-asserted-by":"crossref","DOI":"10.3791\/52462","article-title":"Validation of nanobody and antibody based in vivo tumor xenograft nirf-imaging experiments in mice using ex vivo flow cytometry and microscopy","author":"Bannas","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.phrs.2020.104790_bib0050","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00018-019-03305-z","article-title":"Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer","volume":"77","author":"Akbarzadeh Khiavi","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2020.104790_bib0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15171\/bi.2020.04","article-title":"Pegylated gold nanoparticles-ribonuclease induced oxidative stress and apoptosis in colorectal cancer cells","volume":"10","author":"Akbarzadeh Khiavi","year":"2020","journal-title":"Bioimpacts"},{"key":"10.1016\/j.phrs.2020.104790_bib0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-61779-921-1_6","article-title":"Expression, purification, and characterization of engineered antibody ch2 and vh domains","volume":"899","author":"Gong","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2020.104790_bib0065","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","article-title":"Identification of t-cell receptors targeting kras-mutated human tumors","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1055-9965.1253.13.7","article-title":"Familial risk for colorectal cancers are mainly due to heritable causes","volume":"13","author":"Hemminki","year":"2004","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.phrs.2020.104790_bib0075","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10529-017-2303-8","article-title":"Novel biotechnology approaches in colorectal cancer diagnosis and therapy","volume":"39","author":"Kavousipour","year":"2017","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.phrs.2020.104790_bib0080","series-title":"The Genetics of Sporadic Colon Cancer. Seminars in Colon and Rectal Surgery","first-page":"128","author":"Chung","year":"2004"},{"key":"10.1016\/j.phrs.2020.104790_bib0085","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0092-8674(90)90186-I","article-title":"A genetic model for colorectal tumorigenesis","volume":"61","author":"Fearon","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.104790_bib0090","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/25292","article-title":"Genetic instabilities in human cancers","volume":"396","author":"Lengauer","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104790_bib0095","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1038\/sj.onc.1210059","article-title":"Colorectal cancer and genetic alterations in the wnt pathway","volume":"25","author":"Segditsas","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2020.104790_bib0100","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.cell.2015.05.033","article-title":"Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer","volume":"161","author":"Dow","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.104790_bib0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jso.23706","article-title":"Hereditary colorectal cancer syndromes and genetic testing","volume":"111","author":"Macaron","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.phrs.2020.104790_bib0110","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3748\/wjg.v20.i8.1898","article-title":"Intestinal stem cells and the colorectal cancer microenvironment","volume":"20","author":"Ong","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.104790_bib0115","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1200\/JCO.2008.17.5950","article-title":"Feasibility of screening for lynch syndrome among patients with colorectal cancer","volume":"26","author":"Hampel","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2020.104790_bib0120","first-page":"19","article-title":"Genetic alterations in colorectal cancer","volume":"5","author":"Armaghany","year":"2012","journal-title":"Gastrointest. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using david bioinformatics resources","volume":"4","author":"Huang da","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.phrs.2020.104790_bib0130","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1093\/nar\/gkr988","article-title":"Kegg for integration and interpretation of large-scale molecular data sets","volume":"40","author":"Kanehisa","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0135","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: A database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0140","doi-asserted-by":"crossref","first-page":"D445","DOI":"10.1093\/nar\/gkz862","article-title":"The metacyc database of metabolic pathways and enzymes-a 2019 update","volume":"48","author":"Caspi","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13062-016-0153-2","article-title":"Long range personalized cancer treatment strategies incorporating evolutionary dynamics","volume":"11","author":"Yeang","year":"2016","journal-title":"Biol. Direct"},{"key":"10.1016\/j.phrs.2020.104790_bib0150","doi-asserted-by":"crossref","first-page":"E6010","DOI":"10.1073\/pnas.1803155115","article-title":"Cancer-mutation network and the number and specificity of driver mutations","volume":"115","author":"Iranzo","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2020.104790_bib0155","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.jmb.2018.06.016","article-title":"The emerging potential for network analysis to inform precision cancer medicine","volume":"430","author":"Ozturk","year":"2018","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2020.104790_bib0160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2017.10.036","article-title":"Targeted cancer therapy through antibody fragments-decorated nanomedicines","volume":"268","author":"Alibakhshi","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2020.104790_bib0165","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2009.08.003","article-title":"Differential tumor-targeting abilities of three single-domain antibody formats","volume":"289","author":"Bell","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2020.104790_bib0175","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104790_bib0180","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0185","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1096\/fj.07-8661com","article-title":"Single domain antibodies from llama effectively and specifically block t cell ecto-adp-ribosyltransferase art2.2 in vivo","volume":"21","author":"Koch-Nolte","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2020.104790_bib0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0195","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/08820139.2010.542228","article-title":"Nanobody; an old concept and new vehicle for immunotargeting","volume":"40","author":"Rahbarizadeh","year":"2011","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.phrs.2020.104790_bib0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.phrs.2020.104790_bib0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/bi0009082","article-title":"Thermal unfolding of a llama antibody fragment: a two-state reversible process","volume":"40","author":"Perez","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2020.104790_bib0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0065-3233(02)61004-6","article-title":"Molecular recognition in antibody-antigen complexes","volume":"61","author":"Sundberg","year":"2002","journal-title":"Adv. Protein Chem."},{"key":"10.1016\/j.phrs.2020.104790_bib0215","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1016\/j.vaccine.2005.05.017","article-title":"Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins","volume":"23","author":"Harmsen","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.phrs.2020.104790_bib0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11307-008-0133-8","article-title":"Spect imaging with 99mtc-labeled egfr-specific nanobody for in vivo monitoring of egfr expression","volume":"10","author":"Huang","year":"2008","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.phrs.2020.104790_bib0225","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2967\/jnumed.107.048538","article-title":"Comparison of the biodistribution and tumor targeting of two 99mtc-labeled anti-egfr nanobodies in mice, using pinhole spect\/micro-ct","volume":"49","author":"Gainkam","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.phrs.2020.104790_bib0230","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","article-title":"Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology","volume":"7","author":"Tijink","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.104790_bib0235","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1074\/jbc.M007734200","article-title":"Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs","volume":"276","author":"Els Conrath","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.104790_bib0240","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104790_bib0245","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14712598.8.6.759","article-title":"Complement and cellular cytotoxicity in antibody therapy of cancer","volume":"8","author":"Wang","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.phrs.2020.104790_bib0250","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/pbi.12094","article-title":"Fusion of an fc chain to a vhh boosts the accumulation levels in arabidopsis seeds","volume":"11","author":"De Buck","year":"2013","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.phrs.2020.104790_bib0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pep.2016.03.004","article-title":"Construction and expression of an anti-vegfr2 nanobody-fc fusionbody in ns0 host cell","volume":"123","author":"Qasemi","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.phrs.2020.104790_bib0260","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fimmu.2017.00653","article-title":"Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases","volume":"8","author":"Fernandes","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0265","doi-asserted-by":"crossref","first-page":"e2371","DOI":"10.1371\/journal.pone.0002371","article-title":"Antibody complementarity-determining regions (cdrs) can display differential antimicrobial, antiviral and antitumor activities","volume":"3","author":"Polonelli","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104790_bib0270","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2020.104790_bib0275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00430-009-0116-7","article-title":"Single domain antibodies: promising experimental and therapeutic tools in infection and immunity","volume":"198","author":"Wesolowski","year":"2009","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0280","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrc1075","article-title":"Tumour-cell invasion and migration: diversity and escape mechanisms","volume":"3","author":"Friedl","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0285","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fphar.2015.00283","article-title":"Role of erbb receptors in cancer cell migration and invasion","volume":"6","author":"Appert-Collin","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104790_bib0290","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ctrv.2013.09.008","article-title":"Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance","volume":"40","author":"Mallini","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2020.104790_bib0295","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2559.2008.03165.x","article-title":"Egfr, her-2 and cox-2 levels in colorectal cancer","volume":"53","author":"Antonacopoulou","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.phrs.2020.104790_bib0300","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SLA.0b013e3181bc9d96","article-title":"Activating kras mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab","volume":"251","author":"Yen","year":"2010","journal-title":"Ann. Surg."},{"key":"10.1016\/j.phrs.2020.104790_bib0305","first-page":"61","article-title":"The epidermal growth factor receptor pathway and its inhibition as anticancer therapy","volume":"39","author":"Janmaat","year":"2003","journal-title":"Drugs Today"},{"key":"10.1016\/j.phrs.2020.104790_bib0310","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2004.06.002","article-title":"Epidermal growth factor receptor in tumor angiogenesis","volume":"18","author":"Ellis","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.phrs.2020.104790_bib0315","first-page":"19","article-title":"Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells","volume":"1","author":"Radinsky","year":"1995","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0320","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/onc.2011.409","article-title":"Hyperactive egf receptor, jaks and stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells","volume":"31","author":"Yue","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2020.104790_bib0325","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2217\/nnm.14.178","article-title":"Van Bergen en Henegouwen PM. Nanobody-based cancer therapy of solid tumors","volume":"10","author":"Kijanka","year":"2015","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.phrs.2020.104790_bib0330","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.molimm.2015.01.010","article-title":"Inhibition of angiogenesis in human endothelial cell using vegf specific nanobody","volume":"65","author":"Kazemi-Lomedasht","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0335","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2013.08.298","article-title":"Targeting tumors with nanobodies for cancer imaging and therapy","volume":"172","author":"Oliveira","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2020.104790_bib0340","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.str.2013.05.008","article-title":"Van Bergen en Henegouwen PM, Ferguson KM. Structural evaluation of egfr inhibition mechanisms for nanobodies\/vhh domains","volume":"21","author":"Schmitz","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.phrs.2020.104790_bib0345","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","article-title":"Efficient inhibition of egfr signaling and of tumour growth by antagonistic anti-efgr nanobodies","volume":"56","author":"Roovers","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.phrs.2020.104790_bib0350","doi-asserted-by":"crossref","first-page":"25597","DOI":"10.18632\/oncotarget.25390","article-title":"From mono-to bivalent: improving theranostic properties of target modules for redirection of unicar t cells against egfr-expressing tumor cells in vitro and in vivo","volume":"9","author":"Albert","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2020.104790_bib0355","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1038\/s41598-017-02483-9","article-title":"Bi-specific molecule against egfr and death receptors simultaneously targets proliferation and death pathways in tumors","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104790_bib0360","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/ijc.26145","article-title":"A biparatopic anti-egfr nanobody efficiently inhibits solid tumour growth","volume":"129","author":"Roovers","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0365","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"Swiss-model: Homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0370","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/bioinformatics\/btq444","article-title":"Ultra-fast fft protein docking on graphics processors","volume":"26","author":"Ritchie","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.phrs.2020.104790_bib0375","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1023\/A:1016064930502","article-title":"Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique","volume":"13","author":"Muller","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0380","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2012.11.007","article-title":"Nanobody-albumin nanoparticles (nanaps) for the delivery of a multikinase inhibitor 17864 to egfr overexpressing tumor cells","volume":"165","author":"Altintas","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2020.104790_bib0385","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jconrel.2016.03.014","article-title":"Egfr targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer","volume":"229","author":"van Driel","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2020.104790_bib0390","first-page":"5171","article-title":"Kras mutation testing in metastatic colorectal cancer","volume":"18","author":"Tan","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.104790_bib0395","first-page":"567","article-title":"K-ras gene mutation status in colorectal cancer: comparative analysis of pyrosequencing and pcr-rflp","volume":"54","author":"Dobre","year":"2013","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.phrs.2020.104790_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(01)00528-6","article-title":"Ras and rho regulation of the cell cycle and oncogenesis","volume":"171","author":"Pruitt","year":"2001","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2020.104790_bib0405","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt373","article-title":"Role of oncogenic k-ras in cancer stem cell activation by aberrant wnt\/beta-catenin signaling","volume":"106","author":"Moon","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2020.104790_bib0410","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1200\/JCO.2011.40.9243","article-title":"Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized everest study","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2020.104790_bib0415","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/187152012799014968","article-title":"Are kras\/braf mutations potent prognostic and\/or predictive biomarkers in colorectal cancers?","volume":"12","author":"Yokota","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.phrs.2020.104790_bib0420","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/bjc.2015.37","article-title":"Correlation of extended ras and pik3ca gene mutation status with outcomes from the phase iii agitg max study involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin c in advanced colorectal cancer","volume":"112","author":"Price","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0425","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"Braf mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104790_bib0430","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/418934a","article-title":"Tumorigenesis: Raf\/ras oncogenes and mismatch-repair status","volume":"418","author":"Rajagopalan","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104790_bib0435","volume":"7","author":"de Bruin","year":"2017"},{"key":"10.1016\/j.phrs.2020.104790_bib0440","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","article-title":"Molecular genetics of colorectal cancer","volume":"6","author":"Fearon","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.phrs.2020.104790_bib0445","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gde.2004.12.008","article-title":"A heavily dictated dictator of life and death","volume":"15","author":"P53","year":"2005","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.phrs.2020.104790_bib0450","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/humu.10187","article-title":"The umd-p53 database: new mutations and analysis tools","volume":"21","author":"Beroud","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.phrs.2020.104790_bib0455","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2168.2002.02120.x","article-title":"The colorectal adenoma-carcinoma sequence","volume":"89","author":"Leslie","year":"2002","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.phrs.2020.104790_bib0460","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/1751-7915.12819","article-title":"Escherichia coli surface display for the selection of nanobodies","volume":"10","author":"Salema","year":"2017","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.phrs.2020.104790_bib0465","doi-asserted-by":"crossref","first-page":"12928","DOI":"10.1093\/nar\/gku962","article-title":"A nanobody modulates the p53 transcriptional program without perturbing its functional architecture","volume":"42","author":"Bethuyne","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0470","series-title":"Intracellular Displacement of p53 Using Transactivation Domain (p53 Tad) Specific Nanobodies","first-page":"1045","author":"Steels","year":"2018"},{"key":"10.1016\/j.phrs.2020.104790_bib0475","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.hoc.2004.05.002","article-title":"Angiogenesis in colorectal cancer: therapeutic implications and future directions","volume":"18","author":"Allen","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.phrs.2020.104790_bib0480","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0485","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1158\/0008-5472.CAN-04-1668","article-title":"Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy","volume":"65","author":"Huber","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0490","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104790_bib0495","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/cncr.26540","article-title":"Mechanisms of resistance to vascular endothelial growth factor blockade","volume":"118","author":"Abdullah","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0500","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3389\/fimmu.2017.01746","article-title":"Nanobodies as novel agents for targeting angiogenesis in solid cancers","volume":"8","author":"Arezumand","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0505","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2014.02.069","article-title":"A nanobody directed to a functional epitope on vegf, as a novel strategy for cancer treatment","volume":"446","author":"Farajpour","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2020.104790_bib0510","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s12010-015-1695-y","article-title":"Production of novel vhh nanobody inhibiting angiogenesis by targeting binding site of vegf","volume":"176","author":"Ebrahimizadeh","year":"2015","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.phrs.2020.104790_bib0515","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2011.11.013","article-title":"Generation and characterization of a functional nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor","volume":"50","author":"Behdani","year":"2012","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0520","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/aps.2016.2","article-title":"Generation and characterization of a human nanobody against vegfr-2","volume":"37","author":"Ma","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2020.104790_bib0525","first-page":"3153","article-title":"Anti-egfr-irgd recombinant protein conjugated silk fibroin nanoparticles for enhanced tumor targeting and antitumor efficiency","volume":"9","author":"Bian","year":"2016","journal-title":"Onco. Ther."},{"key":"10.1016\/j.phrs.2020.104790_bib0530","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.biomaterials.2012.09.064","article-title":"Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy","volume":"34","author":"Talelli","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.phrs.2020.104790_bib0535","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2011.12.027","article-title":"Tumor-targeted nanobullets: anti-egfr nanobody-liposomes loaded with anti-igf-1r kinase inhibitor for cancer treatment","volume":"159","author":"van der Meel","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2020.104790_bib0540","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nbt.2012.09.002","article-title":"Development of vegfr2-specific nanobody pseudomonas exotoxin a conjugated to provide efficient inhibition of tumor cell growth","volume":"30","author":"Behdani","year":"2013","journal-title":"N. Biotechnol."},{"key":"10.1016\/j.phrs.2020.104790_bib0545","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17425247.2019.1614911","article-title":"Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors","volume":"16","author":"Jafari","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.phrs.2020.104790_bib0550","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-03-3935","article-title":"Efficient cancer therapy with a nanobody-based conjugate","volume":"64","author":"Cortez-Retamozo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0555","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4161\/19420862.2015.989023","article-title":"Functional inhibition of beta-catenin-mediated wnt signaling by intracellular vhh antibodies","volume":"7","author":"Newnham","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.phrs.2020.104790_bib0560","doi-asserted-by":"crossref","first-page":"145","DOI":"10.12688\/f1000research.4410.2","article-title":"Cykeggparser: Tailoring kegg pathways to fit into systems biology analysis workflows","volume":"3","author":"Nersisyan","year":"2014","journal-title":"F1000Res"},{"key":"10.1016\/j.phrs.2020.104790_bib0565","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7150\/thno.10084","article-title":"Small sized egfr1 and her2 specific bifunctional antibody for targeted cancer therapy","volume":"5","author":"Ding","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2020.104790_bib0570","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12022-014-9345-4","article-title":"The cancer genome atlas research network: a sight to behold","volume":"25","author":"Giordano","year":"2014","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.phrs.2020.104790_bib0575","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nmeth.4000","article-title":"Docm: a database of curated mutations in cancer","volume":"13","author":"Ainscough","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.phrs.2020.104790_bib0580","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"Cosmic: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2020.104790_bib0585","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nmeth.2642","article-title":"Intogen-mutations identifies cancer drivers across tumor types","volume":"10","author":"Gonzalez-Perez","year":"2013","journal-title":"Nat. Methods"},{"key":"10.1016\/j.phrs.2020.104790_bib0590","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.1145720","article-title":"The genomic landscapes of human breast and colorectal cancers","volume":"318","author":"Wood","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.phrs.2020.104790_bib0595","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104790_bib0600","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1038\/s41598-019-41015-5","article-title":"Burden of unique and low prevalence somatic mutations correlates with cancer survival","volume":"9","author":"Klebanov","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2020.104790_bib0605","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.phrs.2020.104790_bib0610","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant mhc class ii epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104790_bib0615","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2015.12.001","article-title":"Mutanome directed cancer immunotherapy","volume":"39","author":"Vormehr","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.phrs.2020.104790_bib0620","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2020.104790_bib0625","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0630","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8103142","article-title":"Neoantigens derived from recurrently mutated genes as potential immunotherapy targets for gastric cancer","volume":"2019","author":"Zhou","year":"2019","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.phrs.2020.104790_bib0635","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase i study of 68ga-her2-nanobody for pet\/ct assessment of her2 expression in breast carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.phrs.2020.104790_bib0640","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.biopha.2017.08.033","article-title":"Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating nf-kappab\/akt\/pten\/mapk pathways","volume":"94","author":"Zununi Vahed","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2020.104790_bib0645","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1186\/s12885-019-6051-0","article-title":"Combined targeting of her-2 and her-3 represents a promising therapeutic strategy in colorectal cancer","volume":"19","author":"Conradi","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2020.104790_bib0650","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase i\/ii trial of labetuzumab govitecan (anti-ceacam5\/sn-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2020.104790_bib0655","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-19-0452","article-title":"U3-1402, a novel her3-targeting antibody-drug conjugate, for the treatment of colorectal cancer","volume":"18","author":"Koganemaru","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2020.104790_bib0660","first-page":"1","article-title":"Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumors","author":"Alizadeh","year":"2020","journal-title":"J. Drug Target."},{"key":"10.1016\/j.phrs.2020.104790_bib0665","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"Ligplot+: multiple ligand-protein interaction diagrams for drug discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820310987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820310987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:11:39Z","timestamp":1760911899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820310987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":133,"alternative-id":["S1043661820310987"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104790","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104790"}}